Statin Therapy and Outcomes After PCI

doi:N/A

Bangaldesh Journal of Cardivascular Medicine

2026, Volume 4, Issue 2 : 1-7

Research Article

Statin Therapy and Outcomes After PCI

Michael R. Anderson

Sarah T. Bennett

Ahmed K. Rahman

Priya x L. Cooper

⁴

David L. Cooper

⁵

Heart Institute of North America, Chicago, USA

Royal Cardiovascular Centre, London, UK

International Medical Research University, Dubai, UAE

⁴

South Asian Heart Institute, New Delhi, India

⁵

Global Cardiovascular Sciences Center, Toronto, Canada

Abstract

Background: Statin therapy is a cornerstone of secondary prevention after percutaneous coronary intervention (PCI). Beyond lipid lowering, statins provide anti-inflammatory, plaque-stabilizing, and endothelial protective effects that may improve post-PCI outcomes.

Objective: To review the impact of statin therapy on clinical outcomes after PCI, including mortality, myocardial infarction, restenosis, stent thrombosis, and repeat revascularization.

Methods: This narrative review summarizes clinical evidence from randomized trials, registries, meta-analyses, and contemporary cardiovascular prevention guidelines.

Results: High-intensity statin therapy after PCI is associated with reduced major adverse cardiovascular events, lower recurrent myocardial infarction, improved plaque stabilization, and better long-term survival. Early statin loading before PCI may reduce periprocedural myocardial injury, particularly in acute coronary syndrome patients.

Conclusion: Statin therapy should be initiated early and continued long-term after PCI. High-intensity statins are preferred unless contraindicated, with LDL-C targets guiding dose escalation and addition of non-statin agents.

Keywords

Statins

PCI

Drug-eluting stents

LDL cholesterol

Myocardial infarction

Secondary prevention.

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

Bangladesh J. Cardiovasc. Med. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.

Recommended Articles

Drug-Coated Balloons in Peripheral Vascular Interventions

Michael R. Anderson,

Sarah T. Bennett,

Ahmed K. Rahman,

Priya Sharma,

David L. Cooper

1-6

Artificial Intelligence–Assisted Detection of Arrhythmias in Contemporary Cardiology Practice: Diagnostic Performance, Clinical Utility, and Future Perspectives

Arif Rahman,

Nusrat Jahan,

Mahmud Hasan,

Farhana Akter,

Kamal Uddin

1-6

Implantable Cardioverter Defibrillator Outcomes in South Asian Populations

Arvind K. Mehta,

Farhana R. Siddiqui,

Michael J. Carter,

Sameer A. Rahman,

Priya N. Banerjee